The graded crowd leans bullish at 65% confidence.

The calls-vs-puts lean on $XBI, IV rank, the implied move and this week's unusual premium.

What State Street SPDR S&P Biotech ETF's filings actually say: revenue mix, the tone of guidance, and the risks buried in the fine print.

Every bond, lease and credit line: when each comes due, and whether cash on hand covers it.

Which senators and representatives traded $XBI: the dates, the sizes, and which way they leaned.

Which smart-money funds built, added to, or trimmed their $XBI stake last quarter.

Every analyst rating and price target on $XBI, and how they have shifted over time.

Every Form 4: insider buys, sells, and which sales were pre-planned months ahead.

Who turned bearish on $XBI before the drop — and how early they called it.

Who bought $XBI near the washout low, and whether the catch actually worked.